KayakerBC,

Zenith is ahead clinically to Constellation Pharma  and has more potential  for drug registration  IMO yet Zenith seems to have an enterprise valuation of $300 Million USD to Constelaltion buyout of $1.8 Billion USD.  There is a disconnect in valuation for both companies in the same epigenetics space.  DM has failed to establish any valuation due to his lack of proper BP management experience... this is sounding  like a broken record falling on deaf ears.  I guess kudos for those buying ZHCLF for .25 USD and even those PP at $1.5 USD per share if Zenith gets sold for over $1.8 Billion at some point.